Dengue Fever
Information
- Disease name
- Dengue Fever
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT02948933 | Active, not recruiting | Cohort Event Monitoring for Dengvaxia®, CYD-TDV Dengue Vaccine | December 14, 2016 | July 1, 2024 | |
| NCT03465254 | Active, not recruiting | Dengue Serostatus Study in the Philippines | November 2016 | June 2023 | |
| NCT04113330 | Active, not recruiting | Surveillance of Suspected Dengue Cases for Access to Care for Subjects Identified as Seronegative or Undetermined Before Receiving CYD Dengue Vaccine in Previous Clinical Studies in Colombia | January 31, 2020 | January 11, 2030 | |
| NCT00384670 | Completed | Phase 1/Phase 2 | A Phase I/II Trial of a Tetravalent Live Attenuated Dengue Vaccine in Flavivirus Antibody Naïve Children | August 2003 | May 2004 |
| NCT00468858 | Completed | Phase 2 | A Study of Two Doses of WRAIR Dengue Vaccine Administered Six Months Apart to Healthy Adults and Children | July 2007 | April 2010 |
| NCT00617344 | Completed | Phase 2 | Immunogenicity and Safety of Three Formulations of Dengue Vaccines in Healthy Adults Aged 18 to 45 Years in the US | April 17, 2008 | February 2010 |
| NCT00730288 | Completed | Phase 2 | Study of ChimeriVax™ Dengue Tetravalent Vaccine in Adult Subjects | August 2006 | January 2008 |
| NCT00740155 | Completed | Phase 2 | Safety and Immunogenicity of Formulations of Dengue Vaccines in Healthy Flavivirus-Naïve Adults | August 2008 | January 2010 |
| NCT00788151 | Completed | Phase 2 | Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Peruvian Children Aged 2 to 11 Years | September 26, 2008 | August 16, 2010 |
| NCT00831012 | Completed | Phase 1 | Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3delta30/31-7164) in Healthy Adults | September 2009 | |
| NCT00842530 | Completed | Phase 2 | Efficacy and Safety of Dengue Vaccine in Healthy Children | February 2009 | February 2014 |
| NCT00875524 | Completed | Phase 2 | Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Subjects | March 2009 | December 2014 |
| NCT00880893 | Completed | Phase 2 | Study of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Subjects in Singapore | April 7, 2009 | October 14, 2014 |
| NCT00920517 | Completed | Phase 1 | Safety and Immune Response to Two Doses of rDEN2/4delta30 Dengue Vaccine | January 2009 | January 2010 |
| NCT00936429 | Completed | Phase 1 | Study of HBV-001 D1 in Healthy Adults | July 2009 | January 2011 |
| NCT00946218 | Completed | Diagnosis and Characterization of Dengue Fever in Children | July 2009 | December 2009 | |
| NCT00993447 | Completed | Phase 2 | Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents in Latin America | October 2009 | March 2012 |
| NCT01030211 | Completed | N/A | Adult Dengue Platelet Study | January 2010 | December 2014 |
| NCT01064141 | Completed | Phase 2 | A Study of Dengue Vaccine in Healthy Toddlers Aged 12 to 15 Months in the Philippines | January 2010 | November 2012 |
| NCT00089908 | Completed | Phase 1 | Safety of and Immune Response to a Dengue Virus Vaccine (rDEN1delta30) in Healthy Adults | September 2004 | November 2005 |
| NCT01218906 | Completed | Prospective Surveillance of Febrile Illness for Dengue-Endemic Areas in Asia | August 2010 | March 2012 | |
| NCT01224639 | Completed | Phase 1 | Safety and Immunogenicity Study to Assess TDV, a Live Attenuated Tetravalent Vaccine for Prevention of Dengue Fever | October 11, 2010 | November 9, 2011 |
| NCT01254422 | Completed | Phase 3 | Study of a Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 11 Years in Malaysia | December 2, 2010 | January 2013 |
| NCT01293331 | Completed | Study of Febrile Illness for Dengue-Endemic Areas in Latin America | August 2010 | April 2012 | |
| NCT01373281 | Completed | Phase 3 | Study of a Novel Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 14 Years in Asia | June 3, 2011 | November 21, 2017 |
| NCT01374516 | Completed | Phase 3 | Study of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America | June 8, 2011 | March 5, 2018 |
| NCT01421732 | Completed | Laboratory Diagnosis and Prognosis of Severe Dengue | October 2010 | December 2014 | |
| NCT01443247 | Completed | N/A | Role of Andi-d in Dengue Fever: a Pilot Study | September 2010 | September 2011 |
| NCT01477671 | Completed | Prospective Dengue Seroprevalence Study in 5 to 10 Year-old Children | September 2011 | December 2013 | |
| NCT01488890 | Completed | Phase 2 | Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Given With or Without Yellow Fever Vaccine | December 6, 2011 | September 27, 2013 |
| NCT01502358 | Completed | Phase 1 | Evaluation of the Safety and the Ability of a DNA Vaccine to Protect Against Dengue Disease | December 2011 | December 2013 |
| NCT01502735 | Completed | Phase 1 | Safety Study of a Vaccine (DENV-1 PIV) to Prevent Dengue Disease | December 2011 | September 2013 |
| NCT01550016 | Completed | International Research Consortium on Dengue Risk Assessment, Management, and Surveillance | October 2011 | October 2016 | |
| NCT01550289 | Completed | Phase 2 | Study of a Tetravalent Dengue Vaccine in Healthy Adult Subjects Aged 18 to 45 Years in India | March 2012 | February 2014 |
| NCT01619969 | Completed | Phase 1/Phase 2 | Celgosivir as a Treatment Against Dengue | July 2012 | July 2013 |
| NCT01666652 | Completed | Phase 1 | A Two-dose Primary Vaccination Study of a Tetravalent Dengue Virus Purified Inactivated Vaccine vs. Placebo in Healthy Adults | September 2012 | November 2017 |
| NCT01702857 | Completed | Phase 1 | A Two-dose Primary Vaccination Study of a Tetravalent Dengue Virus Purified Inactivated Vaccine vs. Placebo in Healthy Adults (in Puerto Rico) | November 2012 | March 23, 2017 |
| NCT01728792 | Completed | Phase 1 | Impact of SC vs IM Administration of DENVax (TDV) on Safety and Immunogenicity | January 22, 2013 | November 21, 2013 |
| NCT01917422 | Completed | Clinical Specimens Testing Program of Dengue Antigen Detection Reagents | July 2012 | June 2013 | |
| NCT01943825 | Completed | Phase 2 | Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity After CYD Tetravalent Dengue Vaccine | November 5, 2013 | November 25, 2015 |
| NCT01983553 | Completed | Long-Term Study of Hospitalized Dengue & Safety in Thai Children Included in a Tetravalent Dengue Vaccine Efficacy Study | September 10, 2013 | August 2016 | |
| NCT02193087 | Completed | Phase 2 | Safety and Immunogenicity of Three Formulations of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) | August 6, 2014 | May 19, 2015 |
| NCT02302066 | Completed | Phase 2 | Safety and Immunogenicity of Different Schedules of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Healthy Participants | December 5, 2014 | February 18, 2019 |
| NCT02425098 | Completed | Phase 2 | Safety and Immunogenicity With Two Different Serotype 2 Potencies of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Adults in Singapore | June 3, 2015 | September 18, 2017 |
| NCT02510638 | Completed | The Clinical Epidemiology of Hospitalized Dengue Cases in Malaysia | September 2015 | December 2015 | |
| NCT02510690 | Completed | Factors Associated With Poor Dengue Outcomes in Malaysia | October 2014 | May 2016 | |
| NCT01134263 | Completed | Phase 3 | Study of a Tetravalent Dengue Vaccine in Healthy Adults in Australia | October 5, 2010 | February 2013 |
| NCT00094705 | Completed | Phase 1 | Safety of and Immune Response to a Dengue Virus Vaccine (rDEN2/4delta30[ME]) in Healthy Adults | January 2005 | April 2006 |
| NCT00270699 | Completed | Phase 1 | Safety of and Immune Response to a Dengue Virus Vaccine (rDEN4delta30-200,201) in Healthy Adults | June 2006 | December 2009 |
| NCT02623725 | Completed | Phase 2 | Study of a Booster Dose of a Tetravalent Dengue Vaccine in Subjects Who Previously Completed the 3-dose Schedule | April 14, 2016 | October 28, 2018 |
| NCT02628444 | Completed | Phase 2 | Immunogenicity and Safety of Different Vaccination Schedules of Tetravalent Dengue Vaccine in Healthy Subjects 9 to 50 Years of Age | May 2, 2016 | April 29, 2020 |
| NCT02741128 | Completed | Phase 2 | Safety and Immunogenicity of a Tetravalent Dengue Vaccine in HIV-Positive Adults | October 28, 2019 | January 19, 2023 |
| NCT02824198 | Completed | Phase 2 | Immunogenicity and Safety of a Tetravalent Dengue Vaccine Booster Injection in Subjects Who Previously Completed a 3-dose Schedule | July 1, 2016 | January 18, 2019 |
| NCT02827162 | Completed | Association of Host Genetics With Vaccine Efficacy and Study of Immune Correlates of Risk From a Tetravalent Dengue Vaccine | March 29, 2016 | April 27, 2016 | |
| NCT02979535 | Completed | Phase 3 | Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Cervarix® | November 16, 2016 | March 25, 2019 |
| NCT02993757 | Completed | Phase 3 | Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Gardasil® | December 1, 2016 | May 27, 2019 |
| NCT03423173 | Completed | Phase 3 | Lot-to-lot Consistency of 3 Lots of Tetravalent Dengue Vaccine (TDV) in Non-endemic Country(Ies) for Dengue | February 12, 2018 | January 14, 2019 |
| NCT03534245 | Completed | Investigating Vector-Borne Determinants of Aedes Transmitted Arboviral Infections in Cambodia: An Observational Longitudinal Cohort Study in Children | July 1, 2018 | January 25, 2022 | |
| NCT03620487 | Completed | Detection of Dengue Virus in Plasma of Patients in Nepal | October 26, 2016 | July 31, 2020 | |
| NCT03746015 | Completed | Phase 2 | Immunogenicity and Safety of Tetravalent Dengue Vaccine Candidate (TDV) in Flavivirus-Naïve and Dengue-Immune Adults | December 28, 2018 | March 1, 2021 |
| NCT03771963 | Completed | Phase 3 | Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) at the End of Shelf Life in Healthy Adults | March 28, 2019 | March 13, 2020 |
| NCT03999996 | Completed | Phase 3 | Long-Term Safety and Antibody Persistence of TDV and the Impact of a Booster Dose | November 12, 2019 | May 25, 2024 |
| NCT04313244 | Completed | Phase 3 | Immunogenicity and Safety of Dengue Tetravalent Vaccine (TDV) and Recombinant 9-valent Human Papillomavirus Vaccine (9vHPV) in Participants Aged ≥9 to <15 Years | May 15, 2021 | July 19, 2022 |
| NCT04434846 | Completed | Sylvatic Transmission of Zika, Dengue, and Chikungunya Viruses in Thailand and Cambodia | February 8, 2021 | May 7, 2021 | |
| NCT05580731 | Completed | Evaluation Study of Dengue RDTs | July 31, 2022 | June 28, 2023 | |
| NCT06388785 | Not yet recruiting | A Study to Monitor the Adverse Events of QDENGA Vaccine in Participants in Malaysia | June 1, 2024 | September 1, 2027 | |
| NCT04597437 | Recruiting | Early Phase 1 | Zanamivir Treatment of Vascular Permeability in Dengue (ZAP-DENGUE) | March 15, 2024 | September 30, 2025 |
| NCT04514107 | Recruiting | N/A | A Cluster-randomized Trial to EValuate the Efficacy of Wolbachia-InfecTed Aedes Aegypti Mosquitoes in Reducing the Incidence of Arboviral Infection in Brazil (EVITA Dengue) | September 9, 2020 | January 1, 2025 |
| NCT06071481 | Recruiting | Phase 2 | Role of Vitamin D in Prevention of Dengue Haemorrhagic Fever and Dengue Shock Syndrome | June 1, 2023 | February 15, 2024 |
| NCT05218304 | Suspended | N/A | Baromètre Santé Adulte 2021-2022 | July 26, 2021 | May 30, 2022 |
| NCT02992418 | Terminated | Phase 3 | Study of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Adacel® in Healthy Subjects | December 19, 2016 | December 10, 2019 |
| NCT05466240 | Terminated | Phase 2 | Study of AT-752 in Patients With Dengue Infection | April 29, 2022 | January 19, 2023 |
| NCT00688389 | Unknown status | Investigation of the Immuno-regulation and Viral Hepatitis Among Patients With or After Dengue Fever Infection | July 2007 | December 31, 2020 | |
| NCT04235361 | Unknown status | Mobile Point of Care Diagnostic Testing for Ebola Virus Disease in DRC | January 15, 2021 | July 30, 2021 | |
| NCT02045069 | Unknown status | Phase 2/Phase 3 | Efficacy and Safety of Ivermectin Against Dengue Infection | February 2014 | March 2016 |
| NCT04422782 | Unknown status | N/A | New Tools for Predicting Capillary Leak Shock During Dengue Fever | May 14, 2020 | May 14, 2023 |
| NCT02608047 | Unknown status | Studies on the Pathogen, Vector Control and Clinical Treatment of Dengue Fever in Guangzhou | October 2014 | October 2017 | |
| NCT04822441 | Unknown status | Prospective Study on the Risks of Dengue Fever for the Fetus. | March 19, 2021 | March 2023 | |
| NCT02673840 | Unknown status | Phase 4 | Ketotifen as a Treatment for Vascular Leakage During Dengue Fever | March 2015 | July 2017 |
| NCT01973855 | Unknown status | Phase 2 | Chinese and Western Medicine Treatment of Fever Associated With Bleeding Symptoms | January 2012 | December 2015 |
| NCT05407181 | Unknown status | Lymphocyte Count and High Fluorescent Count (HFLC) Correlate With Liver Disorder in Dengue Fever Patients | June 3, 2022 | June 5, 2022 | |
| NCT02569827 | Withdrawn | Phase 1/Phase 2 | Celgosivir or Modipafant as Treatment for Adult Participants With Uncomplicated Dengue Fever in Singapore | December 2018 | August 8, 2019 |
| NCT03875560 | Withdrawn | Phase 2 | IC14 in Adult Patients With Dengue Fever | May 2019 | June 2020 |
- OrphaNumber from OrphaNet (Orphanet)
- 99828